The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production

Clinica Chimica Acta

Volumn 378, Issue 1-2, 2007, Pages 59-65

  Tzang, Bor Show ^a   Tsay, Gregory J ^a,b   Lee, Yi Ju ^a   Li, Chin ^c   Sun, Yu Shu ^b   Hsu, Tsai Ching ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Beta2 glycoprotein I ( 2GPI); Cardiolipin (CL); Human parvovirus B19 (B19); VP1 unique region protein (VP1u)

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; DNA; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN VP1;

ABSORPTION; ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA INFECTIOSUM; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, VIRAL; BETA 2-GLYCOPROTEIN I; CAPSID PROTEINS; CARDIOLIPINS; CHILD; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

PARVOVIRUS;

EID: 33846908525     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.10.016     Document Type: Article

References (40)

1. Young N.S., and Brown K.E. Parvovirus B19. N Engl J Med 350 (2004) 586-597
2. Corcoran A., and Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 53 (2004) 459-475
3. Rayment F.B., Crosdale E., Morris D.J., et al. The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens. J Gen Virol 71 (1990) 2665-2672
4. Modrow S., and Dorsch S. Antibody responses in parvovirus B19 infected patients. Pathol Biol (Paris) 50 (2002) 326-331
5. Ozawa K., Ayub J., Hao Y.-S., et al. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 61 (1987) 2395-2406
6. Kurtzman G.J., Cohen B.J., Field A.M., et al. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84 (1989) 1114-1123
7. Schwarz T.F., Roggendorf M., and Deinhardt F. Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods 20 (1988) 155-168
8. Anderson S., Momoeda M., Kawase M., Kajigaya S., and Young N.S. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology 206 (1995) 626-632
9. Rosenfield S.J., Yoshimoto K., Kajigaya S., et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 89 (1992) 2023-2029
10. Saikawa T., Anderson S., Momoeda M., Kajigaya S., and Young N.S. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 67 (1993) 3004-3009
11. Zuffi E., Manaresi E., Gallinella G., et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 14 (2001) 151-158
12. Kawase M., Momoeda M., Young N.S., and Kajigava S. Most of the VP1 unique region of B19 parvovirus is on the capsid surface. Virology 211 (1995) 359-366
13. Musiani M., Manaresi E., Gallinelal G., et al. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 60 (2000) 347-352
14. Chou T.N., Hsu T.C., Chen R.M., Lin L.I., and Tsay G.J. Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus 9 (2000) 551-554
15. Loizou S., Cazabon J.K., Walport M.J., Tait D., and So A.K. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 40 (1997) 103-108
16. Lehmann H.W., von Landenberg P., and Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2 (2003) 218-223
17. Landenberg P., and Modrow S. Human parvovirus B19 infection and antiphospholipid-syndrome: the 2 sides of one medal?. J Vet Med B Infect Dis Vet Public Health 52 (2005) 353-355
18. Zadori Z., Szelei J., Lacoste M.C., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 1 (2001) 291-302
19. Dorsch S., Leibisch G., Kaufmann B., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 76 (2002) 2014-2018
20. Canaan S., Zadori Z., Ghomashchi F., et al. Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem 279 (2004) 14502-14508
21. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
22. Rubin R.L., Joslin F.G., and Tan E.M. An improved ELISA for anti-native DNA by elimination of interference by anti-histone antibodies. J Immunol Methods 63 (1983) 359-366
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-684
24. Towbin H., Stachelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamid gels to nitrocellulose sheet: procedure and some applications. Proc Natl Acad Sci U S A 76 (1979) 4350-4354
25. Gallinella G., Zuffi E., Gentilomi G., et al. Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases. J Med Virol 71 (2003) 135-139
26. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 70 (2003) 6-11
27. Hsu T.C., and Tsay G.J. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 40 (2001) 152-157
28. Lunardi C., Tiso M., Borgato L., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
29. von Landenberg P., Lehmann H.W., Knoll A., et al. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48 (2003) 1939-1947
30. Lu J., Zhi N., Wong S., and Brown K.F. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 193 (2006) 582-590
31. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., and Meroni P.L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65 (2006) 2-6
32. Harel M., Aron-Maor A., Sherer Y., Blank M., and Shoenfeld Y. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology 210 (2005) 743-747
33. Zhang J., and McCrae K.R. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2-glycoprotein I antibodies. Blood 105 (2005) 1964-1969
34. Raschi E., Testoni C., Bosisio D., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101 (2003) 3495-3500
35. Asherson R.A., and Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 62 (2003) 388-393
36. Pierangeli S.S., and Harris E.N. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 357 (2005) 17-33
37. Matsuura E., Igarashi Y., Fujimoto M., et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148 (1992) 3885-3891
38. Pengo V., Biasiolo A., and Fior M.G. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb Haemost 73 (1995) 29-34
39. Mehdi H., Naqvi A., and Kambon M.I. A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (β2-GPI) is crucial for cardiolipin binding. Eur J Biochem 267 (2000) 1770-1776
40. Igarashi M., Matsuura E., Igarashi Y., et al. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 87 (1996) 3262-3270